IF
IFRX.US InflaRx N.V.
- Market cap
- USD 172M
- P/E
- -
- P/B
- 1.08x
- ROE
- -17.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IFRX.US undervalued?
Graham numberThe Graham number of InflaRx N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InflaRx N.V. fundamental analysis
No fundamental analysis for InflaRx N.V. yet.
InflaRx N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfun…
Full company profileInflaRx N.V. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InflaRx N.V. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 231K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 63.1K | 166K | 29.3K | 0.00 |
| Gross Profit | -35.7K | -68.4K | -180K | -742K | -812K | -791K | -627K | -469K | -3.15M | -7.24M | -232K |
| Operating Income | -6.89M | -19.4M | -37.5M | -56.8M | -33.9M | -47.6M | -32.2M | -44.6M | -52.9M | -48.3M | -26.4M |
| EBITDA | -7.07M | -21.9M | -37.3M | -56.1M | -33.2M | -44.9M | -28.8M | -42.1M | -45.6M | -45.2M | -24.5M |
| Net Income | -8.94M | -24.2M | -29.8M | -53.3M | -34.0M | -45.6M | -29.5M | -42.7M | -46.1M | -45.6M | -24.9M |
| EPS | -0.38 | -2.58 | -1.19 | -2.05 | -1.26 | -1.10 | -0.67 | -0.78 | -0.78 | -0.68 | -0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 29.5M | 124M | 159M | 122M | 88.2M | 125M | 102M | 120M | 76.0M | 55.2M | 161M |
| Total Liabilities | 55.2M | 4.78M | 7.82M | 14.4M | 10.4M | 19.9M | 14.1M | 17.6M | 14.6M | 13.7M | 17.2M |
| Shareholders' Equity | -25.7M | 119M | 151M | 107M | 77.9M | 105M | 88.3M | 103M | 61.4M | 41.5M | 144M |
| Cash & Short-term Investments | 29.1M | 123M | 157M | 115M | 81.1M | 83.4M | 81.8M | 12.8M | 18.4M | 46.4M | 114M |
| Total Debt | 53.4M | 287K | 0.00 | 846K | 559K | 1.43M | 1.36M | 1.12M | 805K | 898K | 810K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.99M | -12.2M | -23.7M | -43.2M | -36.5M | -39.9M | -33.7M | -37.8M | -48.6M | -33.9M | -18.8M |
| Capital Expenditure | 53.0K | 149K | 806K | 595K | 94.2K | 37.8K | 162K | 81.1K | 46.9K | 111K | 135K |
| Free Cash Flow | -5.05M | -12.3M | -24.5M | -43.8M | -36.6M | -40.0M | -33.9M | -37.9M | -48.6M | -34.0M | -19.0M |
| Ratios | |||||||||||
| ROE | - | -20.3% | -19.7% | -49.7% | -43.6% | -43.3% | -33.4% | -41.6% | -75.0% | -109.9% | -17.3% |
| ROA | -30.3% | -19.5% | -18.7% | -43.8% | -38.5% | -36.5% | -28.8% | -35.5% | -60.6% | -82.7% | -15.4% |
| Net Profit Margin | - | -10,492.6% | - | - | - | - | - | -67,630.7% | -27,785.0% | -155,582.1% | - |
| Debt to Equity | - | 0.00x | 0.00x | 0.01x | 0.01x | 0.01x | 0.02x | 0.01x | 0.01x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InflaRx N.V. dividends
InflaRx N.V. has not paid dividends in the last 9 fiscal years.
Who owns InflaRx N.V.
- Insiders 3.21%
- Institutions 73.73%
- Public & others 23.06%
- Shares outstanding 147M
- Free float 98.1M
Top funds holding IFRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Small Cap Growth | 3.29M | 2.23% | 0.00% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 3.20M | 2.17% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 1.68M | 1.14% | 0.00% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 836K | 0.57% | 0.00% | Sep 2026 |
| Strategic Advisers U.S. Total Stock | 306K | 0.21% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 78.8K | 0.05% | 0.00% | Oct 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 55.2K | 0.04% | +1.92% | Oct 2026 |
| Goyer & Göppel Smart Sel Universal | 50.0K | 0.03% | 0.00% | Sep 2026 |
| China Universal Gbl YLBJ QDII CNH | 16.0K | 0.01% | 0.00% | Jun 2026 |
| JHVIT Total Stock Market Index I | 2.57K | 0.00% | 0.00% | Sep 2026 |
Top institutions holding IFRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 22.9M | 15.56% | +189.06% | Jun 2026 |
| TCG Crossover Management, LLC | 14.5M | 9.84% | 0.00% | Jun 2026 |
| FMR Inc | 8.16M | 5.54% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 7.30M | 4.95% | 0.00% | Jun 2026 |
| Kalehua Capital Management LLC | 5.80M | 3.93% | 0.00% | Jun 2026 |
| Spruce Street Capital LP | 5.35M | 3.63% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 3.33M | 2.26% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 3.23M | 2.19% | 0.00% | Jun 2026 |
| Great Point Partners LLC | 3.05M | 2.07% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 3.00M | 2.04% | +1,795.48% | Jun 2026 |
| Ameriprise Financial Inc | 2.57M | 1.75% | 0.00% | Jun 2026 |
| Woodline Partners LP | 2.11M | 1.43% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 2.00M | 1.36% | 0.00% | Jun 2026 |
| Eversept Partners, LP | 1.30M | 0.88% | -25.85% | Jun 2026 |
| Franklin Templeton Inc | 1.04M | 0.70% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 916K | 0.62% | -22.11% | Jun 2026 |
| Jefferies Financial Group Inc | 775K | 0.53% | 0.00% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 711K | 0.48% | +28.31% | Jun 2026 |
| Millennium Management LLC | 567K | 0.38% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 335K | 0.23% | +277.14% | Jun 2026 |
InflaRx N.V. company profile
- Company name
- InflaRx N.V.
- Ticker
- IFRX.US
- ISIN
- NL0012661870
- Exchange
- USA Stocks
- Listed since
- Nov 8, 2017
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 65
- Fiscal year end
- December
- Address
- Winzerlaer Str. 2, Jena, Germany, 07745
- Phone
- 49 3641 508 180
- Website
- inflarx.de
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
InflaRx N.V. management
10- Prof. Renfeng Guo M.D.Co-Founder, Chief Scientific Officer & Executive Director · born 1970
- Dr. Thomas Taapken Ph.D.Chief Financial Officer · born 1965
- Ms. Derval O'CarrollSenior VP and Global Head of Regulatory Affairs & Compliance · born 1966
- Mr. Jan Medina CFAHead of Investor Relations & VP
- Dr. Maria Habel PH.D.VP, Head of Preclinical R&D and QC · born 1982
- Mr. Kofi BoatenVP and Head of Supply Quality & Clinical Trial Supplies
- Mr. Peter Hurt Ph.D.Senior Director and Head of Drug Safety & Pharmacovigiliance
- Mr. Daniel VetterSenior Director & Head of IT
- Dr. Igor OrshanskiySenior Director & Head of Business Development
- Ms. Kirsten CremeringSenior Director & Head of Quality Assurance